Business Context and Reporting Period
Company: SRx Health Solutions, Inc. (SRXH)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026 (Six months ended March 31, 2026)
Business Overview: Following a reverse merger in April 2025 and the subsequent CCAA restructuring of its Canadian pharmacy subsidiary (SRx Canada), the Company's continuing operations consist solely of the "Consumer Products" segment (Halo pet food and wellness). The former Health Solutions segment is classified as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 |
|---|---|---|
| Net Sales | $3.4 million | $6.2 million |
| Gross Profit | $1.3 million (37% margin) | $2.3 million (37% margin) |
| Operating Loss | $(1.8) million | $(5.6) million |
| Net Loss (Continuing Ops) | $(6.4) million | $(15.0) million |
| Cash and Cash Equivalents | $20.5 million | $20.5 million (Balance Sheet) |
| Short-Term Investments | $3.0 million | $3.0 million (Balance Sheet) |
| Convertible Debt (Short-Term) | $22.6 million | $22.6 million (Balance Sheet) |
| Digital Assets | $8.3 million | $8.3 million (Balance Sheet) |
Material Changes vs. Prior Period
- Non-Comparable Prior Periods: Results for the three and six months ended March 31, 2025, are not comparable. The prior period reflected the discontinued Health Solutions (SRx Canada) operations, whereas the current period reflects only the Halo Consumer Products business acquired via reverse merger in April 2025.
- Revenue Growth: Net sales of $3.4 million (Q2 2026) and $6.2 million (YTD 2026) represent the initial revenue generation of the standalone Halo business. Digital channels accounted for 84% of Q2 sales.
- Liquidity Improvement: Cash and cash equivalents increased from $1.3 million (Sept 30, 2025) to $20.5 million (Mar 31, 2026), driven primarily by financing activities including ELOC drawdowns and preferred stock issuances.
- Debt Restructuring: The Company settled its July 2025 convertible notes in October 2025 (recognizing a $3.1 million loss in the prior quarter) and issued a new $20.0 million ELOC Commitment Note in October 2025, which is currently classified as short-term debt.
Guidance, Outlook, and Risks
- Outlook: Management is focused on stabilizing the Halo business, optimizing cost structure, and re-establishing a growth path. The Company is evaluating strategic alternatives, including partnerships and product expansion.
- Capital Markets: The Company has an ELOC (Equity Line of Credit) with a total commitment of $1.0 billion. As of March 31, 2026, approximately $39.0 million in proceeds were generated from share issuances under this agreement. Subsequent to the period end, additional shares were issued and debt converted.
- Key Risks:
- Digital Asset Volatility: The Company holds $8.3 million in digital assets (Bitcoin, Ethereum). Changes in fair value are recognized in net income, creating earnings volatility (e.g., $2.9 million loss in Q2 2026).
- Liquidity and Going Concern: While management asserts sufficient liquidity for the next 12 months, the Company has a history of operating losses and relies on continued access to capital markets.
- Customer Concentration: Two customers represented 90% of gross sales in Q2 2026, and two vendors supplied 92% of inventory purchases.
- Regulatory: Risks related to FDA/FTC compliance for pet food products and evolving regulations regarding digital assets.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue given the high concentration (90%) in two wholesale customers within the Digital channel.
- Digital Asset Exposure: Assess the impact of crypto market volatility on future earnings, as fair value changes flow directly to the income statement.
- Debt Obligations: Review the terms of the $22.6 million ELOC Commitment Note, including conversion features and maturity dates (July 2026).
- Discontinued Operations: Confirm the status of the SRx Canada CCAA proceedings and any potential residual liabilities or asset recoveries.
- Share Dilution: Monitor the ELOC drawdowns and warrant exercises, which have significantly increased the share count (from ~25 million in late 2025 to ~416 million as of March 31, 2026).